Applied DNA implements reverse stock split to bring the Company into compliance with Nasdaq’s $1.00 per share minimum bid price requirement for continued listing on the Nasdaq Capital Market. The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on Friday, March 14, 2025.
About us
We have two core business segments, one focused on supply chain authentication across multiple industries. The second is focused on large scale linear DNA production for diagnostics and vaccines.
- Website
-
http://www.adnas.com
External link for Applied DNA Sciences
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Type
- Public Company
- Specialties
- Textile Supply Chain Protection, Cash-In-Transit Protection, Asset Marking, Crime Prevention, large-scale DNA production, authentication technology, Cannabis, Personal Care, Fertilizer, Printing and Packaging, and COVID-19 Solutions
Locations
-
Primary
Get directions
-
Get directions
50 Health Sciences Dr
Stony Brook, New York 11790, US
Employees at Applied DNA Sciences
-
Sanjay M. Hurry
Executive Director, Investor Relations and Corporate Communications, Applied DNA Sciences, Inc. (NASDAQ: APDN)
-
Judy Murrah
President, Chief Operating Officer at Applied DNA Sciences
-
Brian Viscount
Vice President Biopharma and DNA production at Applied DNA Sciences
-
Heather Berry
Updates
-
Applied DNA Sciences announced the completion of the buildout of its new Good Manufacturing Practices (GMP) manufacturing facility within its Stony Brook, NY headquarters and readiness to accept orders for the manufacture of LineaDNA™ IVT templates that clients can utilize for the production of mRNA clinical trial materials. The facility is undergoing final testing and is expected to be fully operational by the end of the current month. The Company is actively negotiating a supply agreement for GMP IVT template with a mRNA therapeutic developer. #syntheticbiology #EnzymaticDNAProduction #PCR #mRNA #GeneticMedicine #NucleicAcidBasedTherapies #DNAInnovation #CellFreeDNAProduction #SyntheticDNA #BiotechInnovation
-
LineaRx, Inc. will be attending the 43rd Annual J.P. Morgan Healthcare Conference, taking place January 13-16! Schedule an appointment with Clay Shorrock to learn about how our scalable GMP enzymatic DNA manufacturing services can empower the next generation of genetic medicines. #JPM2025 #mRNA #CancerVaccine #PersonalizedCancerVaccine #vaccine #PersonalizedMedicine
-
-
The State Institute for Drug Control of the Czech Republic (SÚKL) approved an application for a Phase I clinical trial of an investigational CD123-specific autologous CAR T-cell therapy by the Institute of Hematology and Blood Transfusion (ÚHKT/Eng: IHBT) in Prague for the treatment of relapsed and/or refractory acute myeloid leukemia (AML). UHKT-CAR123-01 utilizes Applied DNA’s synthetic DNA, Linea™ DNA, as a critical component in its manufacture. #GeneticMedicines #CAR-T #CARtherapies #syntheticDNA #AML #KnowAML #acutemyeloidleukemia
-
Clay Shorrock and Aaron Chung are all smiles on the final day of the 2024 Personalized Cancer Vaccine Summit in Boston! Contact us to learn more about our scalable biomanufacturing services for personalized DNA/RNA vaccines and therapeutics. #mRNA #CancerVaccine #PersonalizedCancerVaccine #vaccine #PersonalizedMedicine
-
-
LineaRx, Inc. is back in Boston this week at the 2024 Personalized Cancer Vaccine Summit, starting today through December 5. Meet with Clay Shorrock and Aaron Chung to learn about our scalable biomanufacturing services for personalized DNA/RNA vaccines and therapeutics. #mRNA #CancerVaccine #PersonalizedCancerVaccine #vaccine #PersonalizedMedicine
-
-
U.S. Customs and Border Protection's Forced Labor Division has published a general guide on isotopic testing and supply chain traceability. While CBP does not endorse any specific laboratory, CertainT Isotope Testing meets CBP's guidance. Our isotopic testing partner, Isotech Labs, is ISO 17025 accredited, conducts proficiency testing, and conducts statistical modeling as part of our method of analysis.
-
This week Applied DNA Sciences will be participating in the 3rd Annual mRNA Process Development & Manufacturing Summit and will co-host seminar with mRNA CDMO Kudo Biotechnology. #syntheticbiology #EnzymaticDNAProduction #PCR #mRNA #GeneticMedicine #NucleicAcidBasedTherapies #DNAInnovation #CellFreeDNAProduction #SyntheticDNA #BiotechInnovation Aaron Chung Clay Shorrock Atsuko Sakurai-Sangria
-
Applied DNA Sciences has received a follow-on order valued at more than $500,000 for a quantity of Linea™ DNA from a global manufacturer of in vitro diagnostics (IVDs). #syntheticbiology #EnzymaticDNAProduction #PCR #mRNA #GeneticMedicine #NucleicAcidBasedTherapies #DNAInnovation #CellFreeDNAProduction #SyntheticDNA #BiotechInnovation